Valuation: Bicycle Therapeutics plc

Market Cap 246M 221M 206M 187M 351M 23.38B 353M 2.47B 966M 12.13B 922M 902M 39.03B P/E 2026 *
-1.35x
P/E 2027 * -1.5x
Enterprise Value -267M -240M -224M -203M -381M -25.42B -384M -2.69B -1.05B -13.19B -1B -981M -42.43B EV / Sales 2026 *
-15.2x
EV / Sales 2027 * -23.6x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.31%
1 week-5.90%
Current month-4.62%
1 month-9.77%
3 months-16.63%
6 months-30.63%
Current year-50.42%
1 week 3.5
Extreme 3.5
3.92
1 month 3.33
Extreme 3.3301
4.04
Current year 3.33
Extreme 3.3301
7.34
1 year 3.33
Extreme 3.3301
9.08
3 years 3.33
Extreme 3.3301
28.67
5 years 3.33
Extreme 3.3301
62.08
10 years 3.33
Extreme 3.3301
62.08
Manager TitleAgeSince
Chief Executive Officer 57 2015-08-31
Director of Finance/CFO 46 2026-01-28
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Director/Board Member 57 2015-08-31
Director/Board Member 63 2021-03-16
Director/Board Member 69 2024-02-19
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Chief Operating Officer

-356 0.0009%
10/5/26 Sell

Chief Operating Officer

-406 0.0011%
10/5/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-3.31%-5.90%-55.57%-82.64% 246M
-2.01%-7.86%+60.74%+70.97% 68.92B
+0.16%+5.61%+6.21%+58.55% 51.9B
+1.81%+4.79%+9.99%+38.56% 48.73B
+0.51%+1.51%+27.96%+31.43% 43.13B
+2.70%-3.66%+307.41%+547.01% 41.48B
+0.69%-3.44%+9.52%+96.59% 39.96B
+0.06%-2.02%+11.25%+43.27% 30.6B
-2.57%-10.35%+34.95%-1.02% 26.01B
-0.39%-6.92%-13.60%-14.40% 22.27B
Average -0.29%-4.71%+39.89%+78.83% 37.32B
Weighted average by Cap. +0.04%-4.28%+54.30%+103.60%

Financials

2026 *2027 *
Net sales 17.53M 15.76M 14.71M 13.33M 25.03M 1.67B 25.19M 177M 68.94M 866M 65.83M 64.4M 2.79B 6.69M 6.01M 5.61M 5.09M 9.55M 637M 9.61M 67.35M 26.3M 330M 25.11M 24.57M 1.06B
Net income -172M -155M -144M -131M -246M -16.37B -247M -1.73B -676M -8.5B -646M -632M -27.33B -175M -157M -147M -133M -250M -16.66B -252M -1.76B -688M -8.65B -657M -643M -27.81B
Net Debt -513M -461M -430M -390M -732M -48.8B -737M -5.16B -2.02B -25.33B -1.93B -1.88B -81.46B -403M -363M -338M -307M -576M -38.38B -579M -4.06B -1.59B -19.92B -1.51B -1.48B -64.07B
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
26-10-14 US$3.510 -3.31% 439,358
26-10-13 US$3.630 -4.47% 457,219
26-10-12 US$3.800 -2.31% 233,482
26-10-09 US$3.890 +2.10% 300,616
26-10-08 US$3.810 +2.14% 338,684
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.510USD
Average target price
9.500USD
Spread / Average Target
+170.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Bicycle Therapeutics plc
  1. Stock Market
  2. Stocks
  3. BCYC Stock